

Systematic Review and Meta-Analysis of the Significance of Heterogeneous Vancomycin-Intermediate *Staphylococcus aureus* Isolates[∇]

Sebastiaan J. van Hal^{1*} and David L. Paterson²

Department of Microbiology and Infectious Diseases, Liverpool Hospital, Liverpool BC, NSW 1087, Sydney, Australia,¹ and University of Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital Campus, Herston, QLD 4029, Australia²

Received 16 August 2010/Returned for modification 21 October 2010/Accepted 2 November 2010

The prevalence of heteroresistant vancomycin-intermediate *Staphylococcus aureus* (hVISA) is 1.3% in published studies. Clinical associations include high-inoculum infections and glycopeptide failure, with hVISA infections associated with a 2.37-times-greater failure rate (95% confidence interval [CI], 1.53 to 3.67) compared to vancomycin-sensitive *Staphylococcus aureus* (VSSA) infections. Despite this, 30-day mortality rates were similar to those for VSSA infections (odds ratio [OR], 1.18; 95% CI, 0.81 to 1.74). The optimal therapy for hVISA requires further study.

In the presence of selection pressure, vancomycin-susceptible *Staphylococcus aureus* (VSSA) isolates are able to transform their cell wall and become less susceptible to vancomycin (51). These vancomycin-intermediate *S. aureus* (VISA) isolates are defined by a vancomycin broth microdilution MIC of 4 to 8 $\mu\text{g/ml}$ (57) and may progress through a precursor phenotype known as heteroresistant vancomycin-intermediate *Staphylococcus aureus* (hVISA) (11). Although the precise definition is disputed, heteroresistance refers to the presence of a resistant subpopulation (typically at a frequency of $\leq 10^{-5}$ to 10^{-6} CFU) in a fully susceptible isolate (a broth microdilution MIC of ≤ 2 $\mu\text{g/ml}$).

Detection. hVISA detection is problematic, as commercial susceptibility platforms use inocula lower than the required threshold. As a consequence, multiple screening and detection methods using higher inocula and growth promotion of resistant subpopulations have been developed. Controversy remains, as some of these methods may select for resistant subpopulations *in vitro* rather than detect the *in vivo* presence of heteroresistance (60). The most accurate and reproducible method is the modified population analysis profile (PAP)-area under the curve (AUC), which utilizes the plot of the number of viable colonies against vancomycin concentration. An AUC ratio of the test strain to the reference strain (Mu3) of ≥ 0.9 confirms an hVISA isolate. However, PAP-AUC use is limited as it is expensive and labor- and time-intensive.

Epidemiology. Following the first documented VISA (Mu50) and hVISA (Mu3) strains from Japan (22, 23), both phenotypes have been reported worldwide. The precise burden of hVISA is difficult to determine given the range of testing methodologies, definitions, and changes in vancomycin susceptibility breakpoints in 2006. This may explain the marked variation in hVISA prevalences detected across institutions, geographical regions, and patient populations, with surveillance

studies generally confirming lower hVISA rates than those for selected clinical isolates. Nevertheless, the overall hVISA prevalence remains low at approximately 1.3% of all methicillin-resistant *S. aureus* (MRSA) isolates tested (Table 1) (1–6, 8, 9, 12–16, 18–20, 22, 24, 29–39, 41–47, 49, 50, 52, 55, 56, 58, 61).

Clinical significance of hVISA. All English-language studies containing the term *S. aureus* and any of the terms reduced susceptibility, intermediate susceptibility, and heteroresistance or heteroresistant to vancomycin or glycopeptides were identified through Medline (2006 to 2010) and reviewed. All articles with clinical details are summarized in Table 2 (2, 4, 5, 8, 16, 24, 28, 31, 33, 37, 38, 41). Considerable heterogeneity exists between studies due to the differing patient populations studied, testing methodologies used, and MRSA isolates selected (i.e., initial blood culture compared to final isolate). Despite this, high-inoculum infections (such as infective endocarditis, osteomyelitis, deep abscesses, and prosthetic device infections) (8, 16, 37) and vancomycin treatment failure (defined as persistent infection or bacteremia duration and/or ongoing signs of infection) (2, 4, 8, 16, 42) were common associations with hVISA infection. After the available data were pooled, the odds of glycopeptide failure were 2.37 times greater for hVISA than for VSSA infections (odds ratio [OR], 2.37; 95% confidence interval [CI], 1.53 to 3.67) (Fig. 1). Since high-inoculum infections are independently associated with bacteremic persistence (therapeutic failure) (10, 17, 31) and *de novo* hVISA infections do not always result in treatment failure, hVISA may reflect the consequence rather than the cause of treatment failure.

Intuitively, persistent bacteremia should result in greater morbidity. However, compared to VSSA infections, hVISA persistence does not lead to more metastatic complications (41). Other parameters of morbidity have not been extensively examined. A significant increase in the mean hospital stay in patients with hVISA infection has been documented in one study (16). Similarly, infection-related complications are generally not reported (secondary to the heterogeneity of the principal diagnosis) except for one study where hVISA infective endocarditis patients were more likely to develop congestive cardiac failure (4).

* Corresponding author. Mailing address: Department of Microbiology and Infectious Diseases, Liverpool Hospital, Locked Bag 7090, Liverpool BC, NSW 1087, Sydney, Australia. Phone: 61-2-9828 5163. Fax: 61-2-9828 5129. E-mail: Sebastian.vanHal@sswhs.nsw.gov.au.

[∇] Published ahead of print on 15 November 2010.

TABLE 1. Prevalence of hVISA based on method of screening/detection, origin of study, and isolate selection

Screening test ^a	Confirmation ^a	Country or region (reference[s])	Isolate source	No. of MRSA isolates	No. (%) of hVISA isolates detected
No screening test	Macromethod Etest	Israel (37, 38)	Blood	487	43 (8.8)
		Singapore (16)	Blood	56	3 (5.4)
		USA (41)	Blood	489	71 (14.5)
	PAP-AUC	Australia (8, 24)	Blood/any	170	64 (37.6)
		World (4)	Blood	65	19 (29.2)
		Japan (42)	Blood	20	2 (10)
	Simplified PAP	USA (14, 45, 56)	Blood	738	3 (0.4)
		Europe (50)	Any	302	0 (0)
		Germany (20)	Any	85	7 (8.2)
Simplified PAP	PAP	Asia (52)	Any	1,357	58 (4.3)
		Spain (2)	Device related	19	14 (73.7)
		Japan (22, 29)	Any	7,774	35 (0.5)
		Korea (32, 33)	Any	4,045	24 (0.6)
		Germany (6)	Any	367	2 (0.5)
Variation of simplified PAP	PAP	Greece (30)	Any	72	1 (1.4)
		Italy (39)	Any	179	2 (1.1)
		Thailand (36, 58)	Any	1,049	15 (1.4)
		France (44)	Any	171	2 (1.2)
		Mexico (12)	Any	152	1 (0.7)
		Belgium (13)	Any	2,145	4 (0.2)
Macromethod Etest	PAP	USA (35)	Any	982	2 (0.2)
	PAP-AUC	USA (46, 47)	Blood/any	3,299	140 (4.2)
		Ireland (15)	Any	3,189	73 (2.3)
		UK (34)	Blood/nasal	2,550	86 (3.4)
		Canada (1)	Any	475	25 (5.3)
Screening agar	PAP	Turkey (49)	Any	256	46 (18)
		Belgium (43)	Nasal/skin	455	3 (0.7)
		Korea (9)	Any	37,856	18 (<0.1)
	PAP-AUC	France (19)	Any	2,300	255 (11.1)
		China (55)	Any	200	26 (13)
		USA (31)	Blood	22	3 (13.6)
		France (5)	Any	48	13 (27.1)
	Simplified PAP MIC based	UK (3)	Any	11,242	0 (0)
		Hong Kong (61)	Blood	52	3 (5.8)
	MIC based	PAP	USA (18)	Blood	30
Total				82,698	1,063 (1.3)

^a Screening and/or confirmation testing included the following tests. For a more detailed discussion on the performance of each test, see reference 25. Simplified population analysis profile (PAP): growth of (1 to 30) colonies on brain heart infusion agar supplemented with 4 mg/liter vancomycin at 48 h is considered positive for hVISA. Variations of simplified PAP include using different inoculum sizes (>10 μ l), inoculum concentrations (>0.5 McFarland standard), media (Mueller-Hinton agar), antibiotics (teicoplanin), and/or vancomycin concentrations (3 or 6 mg/liter). PAP: hVISA is present when the graph of isolated colonies on brain heart infusion agar or Mueller-Hinton agar plotted against increasing vancomycin concentration at 48 h is similar to that for the reference (Mu3) strain. Analysis can be standardized using the area under the curve (PAP-AUC) with hVISA being confirmed when the ratio of the test strain to the control strain (Mu3) is between 0.9 and 1.3. Macromethod (2 McFarland standard) Etest on brain heart infusion agar is defined as positive for hVISA if the vancomycin and teicoplanin MICs are ≥ 8 μ g/ml or the teicoplanin MIC is ≥ 12 μ g/ml for the isolate. Screening agars: ≥ 1 colony isolated after 24 to 48 h on either brain heart infusion agar or Mueller-Hinton agar supplemented with vancomycin or teicoplanin is considered positive for hVISA. MIC-based testing includes standard Etest or vancomycin broth microdilution of resistant subpopulations.

Significance of MIC in hVISA. The proportion of hVISA detected is directly related to increases in vancomycin MIC with the majority (>80%) of hVISA isolates demonstrating an Etest MIC of ≥ 2 μ g/ml (41). Although a detailed discussion of the clinical significance of higher MICs is beyond the scope of this review, several studies have documented greater mortality associated with higher-MIC-susceptible MRSA isolates (generally between 1.5 and 2 μ g/ml) (21, 53). Only one study has examined both variables (vancomycin MIC and heteroresistance phenotype) in the same isolates, with neither variable predictive of overall mortality on multivariate analysis (41).

Thus, the relative contribution of heteroresistance to MIC-related outcomes remains unclear and requires further study.

Mortality and hVISA. Since hVISA is associated with parameters known to influence mortality (i.e., high-inoculum infections, persistent bacteremia, and high vancomycin MICs), one would expect an increased mortality compared to that of VSSA infections (Table 2). However, no study to date has had the power to detect such a difference. After all available data from comparative studies were pooled, hVISA was associated with a 30-day mortality rate similar to that of VSSA infections (OR, 1.18; 95% CI, 0.81 to 1.74) (Fig. 2). These findings can in

TABLE 2. Published studies containing clinical details of hVISA-infected patients

Study (reference no.)	Publication description	No. (%) of hVISA isolates detected ^a	No. (%) of therapeutic failures, hVISA, VSSA	Therapeutic failure definition used in study	No. (%) of infections with 30-day mortality, hVISA, VSSA	Other clinical finding(s)
Ariza et al., 1999 (2)	MRSA orthopedic device infections (<i>n</i> = 19); retrospective	14 (74)	12 (86); 1 (20) (<i>P</i> not stated)	Persistence or reappearance of infection after 6 weeks of therapy	No data	All patients cured following device removal
Kim et al., 2002 (33)	Consecutive <i>S. aureus</i> isolates from any site (<i>n</i> = 3,363); retrospective	24 (0.7)	0: 0	Not stated	3 (14): 0	15 colonized patients; 7 infected patients
Bert et al., 2003 (5)	Consecutive MRSA isolates from any site (<i>n</i> = 48); retrospective	13 (27)	1 (10): 0	Persistent bacteremia of >5 days	1 (7); 6 (17) (<i>P</i> = NS ^b)	3 colonized, 10 infected liver transplant patients
Charles et al., 2004 (8)	MRSA bacteremic patients (<i>n</i> = 53); retrospective	5 (9)	5 (100); 1 (2.1%) (<i>P</i> < 0.01)	Persistent bacteremia and fever for >7 days	1 (20); 17 (35) (<i>P</i> = 0.7)	hVISA associated with high-bacterial load infections (<i>P</i> = 0.001) and initial low VAN ^f levels (<i>P</i> = 0.006)
Howden et al., 2004 (28)	hVISA confirmed bacteremic patients (<i>n</i> = 25); retrospective	25 (100)	19 (76); 0	Persistent bacteremia or positive sterile-site culture (>7 days and 21 days of therapy, respectively)	7 (33): 0	Paired isolates tested with no hVISA phenotype detected in the initial blood isolate
Khosrovaneh et al., 2004 (31)	Persistent and recurrent MRSA bacteremic patients (<i>n</i> = 21); retrospective	3 (13)	Not stated	No data	No data	
Maor et al., 2007 (38)	hVISA confirmed bacteremic patients (<i>n</i> = 264); retrospective	16 (6)	7 (44): 0	Persistent bacteremia of >7 days	12 (75): 0	
Neoh et al., 2007 (42)	Adequately treated (VAN for >5 days with trough levels of >10 µg/ml) MRSA bacteremic patients (<i>n</i> = 20); retrospective	2 (10)	2 (100); 5 (27) (<i>P</i> < 0.01)	Persistence or worsening of symptoms and infection-related mortality	2 (100): 8 (44)	hVISA associated with greater no. of febrile days (<i>P</i> < 0.01) and increased no. of days for CRP ^e to decrease by >30% of maximum value (<i>P</i> < 0.01)
Fong et al., 2009 (16)	Persistent MRSA infection (>7 days of culture positivity) (<i>n</i> = 56); retrospective	3 (5)	56 days for hVISA, VISA vs 46 days for VSSA (<i>P</i> < 0.01); 9/9 (100); 21/26 (80) bacteremic patients ^d	Duration of bacteremia (in days); persistent bacteremia for >7 days ^d	5 (50): 19 (63) (<i>P</i> = 0.48)	hVISA/VISA associated with bone/joint (<i>P</i> < 0.01) and prosthesis (<i>P</i> = 0.04) infections and increased length of hospital stay (<i>P</i> < 0.01)
Maor et al., 2009 (37)	MRSA bacteremic patients (<i>n</i> = 250); retrospective	27 (12)	12 days for hVISA vs 2 days for VSSA (<i>P</i> < 0.01)	Duration of bacteremia (in days)	14 (51): 103 (46) (<i>P</i> = 0.6)	hVISA associated with infective endocarditis (<i>P</i> = 0.007) and osteomyelitis (<i>P</i> = 0.006)
Horne et al., 2009 (24)	Consecutive clinical MRSA isolates (<i>n</i> = 117); prospective	59 (50)	10 (38); 11 (26) (<i>P</i> = 0.08)	Unresolved signs or symptoms of infection following standard therapy or recurrence of infection within 1 mo of cessation of therapy	12 (21): 11 (20) (<i>P</i> = 0.93)	hVISA associated with lower rate of infection (<i>P</i> < 0.003) and bacteremia (<i>P</i> < 0.001)
Bae et al., 2009 (4)	MRSA infective endocarditis cases from the ICE ^c cohort (<i>n</i> = 65); prospective	19 (29)	13 (68); 17 (37) (<i>P</i> = 0.029)	Persistent bacteremia of >3 days despite active antibiotic treatment	8 (42): 16 (35) (<i>P</i> = 0.59)	hVISA associated with congestive cardiac failure (<i>P</i> = 0.033) and older patients (<i>P</i> = 0.057)
Musta et al., 2009 (41)	MRSA bacteremic patients (<i>n</i> = 489); retrospective	71 (17)	20 (47); 101 (42) (<i>P</i> = 0.5)	Persistent bacteremia of >7 days and/or a metastatic infection	14 (43); 43 (27) (<i>P</i> = 0.5)	

^a For details of detection methods, see Table 1.^b NS, not significant.^c Of the 56 patients who met the case definition, 10 cases (3 of hVISA infection and 7 of VISA infection) and 30 randomly assigned controls were selected.^d Data obtained by personal communication.^e ICE, International Collaboration on Endocarditis.^f VAN, vancomycin.^g CRP, C-reactive protein.




FIG. 1. Forest plot (using Mantel-Haenszel analysis) of events denoting vancomycin (VAN) treatment failure (with all definitions regarded the same) in hVISA- compared to VSSA-infected patients. Squares indicate point estimates, and the size of the square indicates the weight of each study. *, data obtained by personal communication.




FIG. 2. Forest plot (using Mantel-Haenszel analysis) of 30-day mortality in hVISA- compared to VSSA-infected patients with “events” denoting deaths in each group. Squares indicate point estimates, and the size of the square indicates the weight of each study.

part be explained by the reduced virulence and decreased host immune responses demonstrated in animal infection models and laboratory studies with hVISA infections (27, 40). A clinical study indirectly supports this link, with hVISA significantly more likely to be associated with colonization rather than infection (24).

Conclusion and therapeutic implications. The role of vancomycin in the treatment of hVISA remains unclear, as heteroresistance may emerge during glycopeptide therapy, especially in infections associated with poor antibiotic penetration (infective endocarditis and osteomyelitis) (8). Despite these deficiencies, no new antibiotic has been documented to be superior to vancomycin (17). Alternative agents have been used successfully in numerous case reports (25). However, potential concerns remain when prescribing these agents. These include toxicity with prolonged linezolid use (7), possible cross-resistance with lipoglycopeptides (54), and the clinical relevance of emerging low-level daptomycin nonsusceptibility during treatment of hVISA infections (48). An important adjunct to antimicrobial therapy and a key component of success is surgical debridement for high-inoculum hVISA infections (26). Irrespective of treatment choice, MRSA bacteremia mortality remains high (59). Therefore, further research should be aimed at developing new agents and defining the

optimal pharmacodynamic parameters of current antibiotics, including vancomycin, in targeting specific clinical contexts.

REFERENCES

- Adam, H. J., L. Louie, C. Watt, D. Gravel, E. Bryce, M. Loeb, A. Matlow, A. McGeer, M. R. Mulvey, and A. E. Simor. 2010. Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995–2006. *Antimicrob. Agents Chemother.* **54**:945–949.
- Ariza, J., M. Pujol, J. Cabo, C. Pena, N. Fernandez, J. Linares, J. Ayats, and F. Gudiol. 1999. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. *Lancet* **353**:1587–1588.
- Aucken, H. M., M. Warner, M. Ganner, A. P. Johnson, J. F. Richardson, B. D. Cookson, and D. M. Livermore. 2000. Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus. *J. Antimicrob. Chemother.* **46**:639–640.
- Bae, I. G., J. J. Federspiel, J. M. Miro, C. W. Woods, L. Park, M. J. Rybak, T. H. Rude, S. Bradley, S. Bukovski, C. G. de la Maria, S. S. Kanj, T. M. Korman, F. Marco, D. R. Murdoch, P. Plesiat, M. Rodriguez-Creixems, P. Reinbott, L. Steed, P. Tattevin, M. F. Tripodi, K. L. Newton, G. R. Corey, and V. G. Fowler, Jr. 2009. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. *J. Infect. Dis.* **200**:1355–1366.
- Bert, F., J. Clarissou, F. Durand, D. Delefosse, C. Chauvet, P. Lefebvre, N. Lambert, and C. Branger. 2003. Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. *J. Clin. Microbiol.* **41**:5147–5152.
- Bierbaum, G., K. Fuchs, W. Lenz, C. Szekat, and H. G. Sahl. 1999. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. *Eur. J. Clin. Microbiol. Infect. Dis.* **18**:691–696.

7. Bishop, E., S. Melvani, B. P. Howden, P. G. Charles, and M. L. Grayson. 2006. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. *Antimicrob. Agents Chemother.* **50**:1599–1602.
8. Charles, P. G., P. B. Ward, P. D. Johnson, B. P. Howden, and M. L. Grayson. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate *Staphylococcus aureus*. *Clin. Infect. Dis.* **38**:448–451.
9. Chung, G., J. Cha, S. Han, H. Jang, K. Lee, J. Yoo, H. Kim, S. Eun, B. Kim, O. Park, and Y. Lee. 2010. Nationwide surveillance study of vancomycin intermediate *Staphylococcus aureus* strains in Korean hospitals from 2001 to 2006. *J. Microbiol. Biotechnol.* **20**:637–642.
10. Cremieux, A. C., B. Maziere, J. M. Vallois, M. Ottaviani, A. Azancot, H. Raffoul, A. Bouvet, J. J. Pocardalo, and C. Carbon. 1989. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. *J. Infect. Dis.* **159**:938–944.
11. Cui, L., X. Ma, K. Sato, K. Okuma, F. C. Tenover, E. M. Mamizuka, C. G. Gemmell, M. N. Kim, M. C. Ploy, N. El-Sohl, V. Ferraz, and K. Hiramatsu. 2003. Cell wall thickening is a common feature of vancomycin resistance in *Staphylococcus aureus*. *J. Clin. Microbiol.* **41**:5–14.
12. Delgado, A., J. T. Riordan, R. Lamichhane-Khadka, D. C. Winnett, J. Jimenez, K. Robinson, F. G. O'Brien, S. A. Cantore, and J. E. Gustafson. 2007. Hetero-vancomycin-intermediate methicillin-resistant *Staphylococcus aureus* isolate from a medical center in Las Cruces, New Mexico. *J. Clin. Microbiol.* **45**:1325–1329.
13. Denis, O., C. Nonhoff, B. Byl, C. Knoop, S. Bobin-Dubreux, and M. J. Struelens. 2002. Emergence of vancomycin-intermediate *Staphylococcus aureus* in a Belgian hospital: microbiological and clinical features. *J. Antimicrob. Chemother.* **50**:383–391.
14. Eguia, J. M., C. Liu, M. Moore, E. M. Wrona, J. Pont, J. L. Gerberding, and H. F. Chambers. 2005. Low colonization prevalence of *Staphylococcus aureus* with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area. *Clin. Infect. Dis.* **40**:1617–1624.
15. Fitzgibbon, M. M., A. S. Rossney, and B. O'Connell. 2007. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant *Staphylococcus aureus* isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate *S. aureus*. *J. Clin. Microbiol.* **45**:3263–3269.
16. Fong, R. K., J. Low, T. H. Koh, and A. Kurup. 2009. Clinical features and treatment outcomes of vancomycin-intermediate *Staphylococcus aureus* (VISA) and heteroresistant vancomycin-intermediate *Staphylococcus aureus* (hVISA) in a tertiary care institution in Singapore. *Eur. J. Clin. Microbiol. Infect. Dis.* **28**:983–987.
17. Fowler, V. G., Jr., H. W. Boucher, G. R. Corey, E. Abrutyn, A. W. Karchmer, M. E. Rupp, D. P. Levine, H. F. Chambers, F. P. Tally, G. A. Vigliani, C. H. Cabell, A. S. Link, I. DeMeyer, S. G. Filler, M. Zervos, P. Cook, J. Parsonnet, J. M. Bernstein, C. S. Price, G. N. Forrest, G. Fatkenheuer, M. Gareca, S. J. Rehm, H. R. Brodt, A. Tice, and S. E. Cosgrove. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by *Staphylococcus aureus*. *N. Engl. J. Med.* **355**:653–665.
18. Franchi, D., M. W. Climo, A. H. Wong, M. B. Edmond, and R. P. Wenzel. 1999. Seeking vancomycin resistant *Staphylococcus aureus* among patients with vancomycin-resistant enterococci. *Clin. Infect. Dis.* **29**:1566–1568.
19. Garnier, F., D. Chainier, T. Walsh, A. Karlsson, A. Bolmstrom, C. Grelaud, M. Mounier, F. Denis, and M. C. Ploy. 2006. A 1 year surveillance study of glycopeptide-intermediate *Staphylococcus aureus* strains in a French hospital. *J. Antimicrob. Chemother.* **57**:146–149.
20. Geisel, R., F. J. Schmitz, L. Thomas, G. Berns, O. Zetsche, B. Ulrich, A. C. Fluit, H. Labischinsky, and W. Witte. 1999. Emergence of heterogeneous intermediate vancomycin resistance in *Staphylococcus aureus* isolates in the Dusseldorf area. *J. Antimicrob. Chemother.* **43**:846–848.
21. Hidayat, L. K., D. I. Hsu, R. Quist, K. A. Shriner, and A. Wong-Beringer. 2006. High-dose vancomycin therapy for methicillin-resistant *Staphylococcus aureus* infections: efficacy and toxicity. *Arch. Intern. Med.* **166**:2138–2144.
22. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of *Staphylococcus aureus* heterogeneously resistant to vancomycin. *Lancet* **350**:1670–1673.
23. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant *Staphylococcus aureus* clinical strain with reduced vancomycin susceptibility. *J. Antimicrob. Chemother.* **40**:135–136.
24. Horne, K. C., B. P. Howden, E. A. Grabsch, M. Graham, P. B. Ward, S. Xie, B. C. Mayall, P. D. Johnson, and M. L. Grayson. 2009. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-susceptible MRSA. *Antimicrob. Agents Chemother.* **53**:3447–3452.
25. Howden, B. P., J. K. Davies, P. D. Johnson, T. P. Stinear, and M. L. Grayson. 2010. Reduced vancomycin susceptibility in *Staphylococcus aureus*, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. *Clin. Microbiol. Rev.* **23**:99–139.
26. Howden, B. P., P. D. Johnson, P. G. Charles, and M. L. Grayson. 2004. Failure of vancomycin for treatment of methicillin-resistant *Staphylococcus aureus* infections. *Clin. Infect. Dis.* **39**:1544.
27. Howden, B. P., D. J. Smith, A. Mansell, P. D. Johnson, P. B. Ward, T. P. Stinear, and J. K. Davies. 2008. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant *Staphylococcus aureus* bacteraemia. *BMC Microbiol.* **8**:39.
28. Howden, B. P., P. B. Ward, P. G. Charles, T. M. Korman, A. Fuller, P. du Cros, E. A. Grabsch, S. A. Roberts, J. Robson, K. Read, N. Bak, J. Hurley, P. D. Johnson, A. J. Morris, B. C. Mayall, and M. L. Grayson. 2004. Treatment outcomes for serious infections caused by methicillin-resistant *Staphylococcus aureus* with reduced vancomycin susceptibility. *Clin. Infect. Dis.* **38**:521–528.
29. Ike, Y., Y. Arakawa, X. Ma, K. Tatewaki, M. Nagasawa, H. Tomita, K. Tanimoto, and S. Fujimoto. 2001. Nationwide survey shows that methicillin-resistant *Staphylococcus aureus* strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. *J. Clin. Microbiol.* **39**:4445–4451.
30. Kantzanou, M., P. T. Tassios, A. Tseleni-Kotsovoli, N. J. Legakis, and A. C. Vatopoulos. 1999. Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant *Staphylococcus aureus*. *J. Antimicrob. Chemother.* **43**:729–731.
31. Khosrovaneh, A., K. Riederer, S. Saeed, M. S. Tabrizi, A. R. Shah, M. M. Hanna, M. Sharma, L. B. Johnson, M. G. Fakhri, and R. Khatib. 2004. Frequency of reduced vancomycin susceptibility and heterogeneous sub-population in persistent or recurrent methicillin-resistant *Staphylococcus aureus* bacteremia. *Clin. Infect. Dis.* **38**:1328–1330.
32. Kim, H. B., W. B. Park, K. D. Lee, Y. J. Choi, S. W. Park, M. D. Oh, E. C. Kim, and K. W. Choe. 2003. Nationwide surveillance for *Staphylococcus aureus* with reduced susceptibility to vancomycin in Korea. *J. Clin. Microbiol.* **41**:2279–2281.
33. Kim, M. N., S. H. Hwang, Y. J. Pyo, H. M. Mun, and C. H. Pai. 2002. Clonal spread of *Staphylococcus aureus* heterogeneously resistant to vancomycin in a university hospital in Korea. *J. Clin. Microbiol.* **40**:1376–1380.
34. Kirby, A., R. Graham, N. J. Williams, M. Wootton, C. M. Broughton, M. Alanazi, J. Anson, T. J. Neal, and C. M. Parry. 2010. *Staphylococcus aureus* with reduced glycopeptide susceptibility in Liverpool, UK. *J. Antimicrob. Chemother.* **65**:721–724.
35. Kosowska-Shick, K., L. M. Ednie, P. McGhee, K. Smith, C. D. Todd, A. Wehler, and P. C. Appelbaum. 2008. Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant *Staphylococcus aureus* at Hershey Medical Center. *Antimicrob. Agents Chemother.* **52**:4510–4513.
36. Lulitanond, A., C. Engchanil, P. Chaimanee, M. Vorachit, T. Ito, and K. Hiramatsu. 2009. The first vancomycin-intermediate *Staphylococcus aureus* strains isolated from patients in Thailand. *J. Clin. Microbiol.* **47**:2311–2316.
37. Maor, Y., M. Hagin, N. Belausov, N. Keller, D. Ben-David, and G. Rahav. 2009. Clinical features of heteroresistant vancomycin-intermediate *Staphylococcus aureus* bacteremia versus those of methicillin-resistant *S. aureus* bacteremia. *J. Infect. Dis.* **199**:619–624.
38. Maor, Y., G. Rahav, N. Belausov, D. Ben-David, G. Smollan, and N. Keller. 2007. Prevalence and characteristics of heteroresistant vancomycin-intermediate *Staphylococcus aureus* bacteremia in a tertiary care center. *J. Clin. Microbiol.* **45**:1511–1514.
39. Marchese, A., G. Balistreri, E. Tonoli, E. A. Debbia, and G. C. Schito. 2000. Heterogeneous vancomycin resistance in methicillin-resistant *Staphylococcus aureus* strains isolated in a large Italian hospital. *J. Clin. Microbiol.* **38**:866–869.
40. McCallum, N., H. Karazum, R. Getzmann, M. Bischoff, P. Majcherczyk, B. Berger-Bachi, and R. Landmann. 2006. In vivo survival of teicoplanin-resistant *Staphylococcus aureus* and fitness cost of teicoplanin resistance. *Antimicrob. Agents Chemother.* **50**:2352–2360.
41. Musta, A. C., K. Riederer, S. Shemes, P. Chase, J. Jose, L. B. Johnson, and R. Khatib. 2009. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant *Staphylococcus aureus* bacteremia: trends over 11 years. *J. Clin. Microbiol.* **47**:1640–1644.
42. Neoh, H. M., S. Hori, M. Komatsu, T. Oguri, F. Takeuchi, L. Cui, and K. Hiramatsu. 2007. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. *Ann. Clin. Microbiol. Antimicrob.* **6**:13.
43. Nonhoff, C., O. Denis, and M. J. Struelens. 2005. Low prevalence of methicillin-resistant *Staphylococcus aureus* with reduced susceptibility to glycopeptides in Belgian hospitals. *Clin. Microbiol. Infect.* **11**:214–220.
44. Reverdy, M. E., S. Jarraud, S. Bobin-Dubreux, E. Burel, P. Girardo, G. Lina, F. Vandenesch, and J. Etienne. 2001. Incidence of *Staphylococcus aureus* with reduced susceptibility to glycopeptides in two French hospitals. *Clin. Microbiol. Infect.* **7**:267–272.
45. Rybak, M. J., R. Cha, C. M. Cheung, V. G. Meka, and G. W. Kaatz. 2005. Clinical isolates of *Staphylococcus aureus* from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. *Diagn. Microbiol. Infect. Dis.* **51**:119–125.
46. Rybak, M. J., S. N. Leonard, K. L. Rossi, C. M. Cheung, H. S. Sader, and

- R. N. Jones. 2008. Characterization of vancomycin-heteroresistant *Staphylococcus aureus* from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). *J. Clin. Microbiol.* **46**:2950–2954.
47. Sader, H. S., R. N. Jones, K. L. Rossi, and M. J. Rybak. 2009. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among *Staphylococcus aureus* causing bloodstream infections in nine USA hospitals. *J. Antimicrob. Chemother.* **64**:1024–1028.
 48. Sakoulas, G., J. Alder, C. Thauvin-Eliopoulos, R. C. Moellering, Jr., and G. M. Eliopoulos. 2006. Induction of daptomycin heterogeneous susceptibility in *Staphylococcus aureus* by exposure to vancomycin. *Antimicrob. Agents Chemother.* **50**:1581–1585.
 49. Sancak, B., S. Ercis, D. Menemenioglu, S. Colakoglu, and G. Hascelik. 2005. Methicillin-resistant *Staphylococcus aureus* heterogeneously resistant to vancomycin in a Turkish university hospital. *J. Antimicrob. Chemother.* **56**:519–523.
 50. Schmitz, F. J., A. Krey, R. Geisel, J. Verhoef, H. P. Heinz, and A. C. Fluit. 1999. Susceptibility of 302 methicillin-resistant *Staphylococcus aureus* isolates from 20 European university hospitals to vancomycin and alternative antistaphylococcal compounds. SENTRY Participants Group. *Eur. J. Clin. Microbiol. Infect. Dis.* **18**:528–530.
 51. Sieradzki, K., and A. Tomasz. 2003. Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of *Staphylococcus aureus*. *J. Bacteriol.* **185**:7103–7110.
 52. Song, J. H., K. Hiramatsu, J. Y. Suh, K. S. Ko, T. Ito, M. Kapi, S. Kiem, Y. S. Kim, W. S. Oh, K. R. Peck, and N. Y. Lee. 2004. Emergence in Asian countries of *Staphylococcus aureus* with reduced susceptibility to vancomycin. *Antimicrob. Agents Chemother.* **48**:4926–4928.
 53. Soriano, A., F. Marco, J. A. Martinez, E. Pisos, M. Almela, V. P. Dimova, D. Alamo, M. Ortega, J. Lopez, and J. Mensa. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant *Staphylococcus aureus* bacteremia. *Clin. Infect. Dis.* **46**:193–200.
 54. Streit, J. M., H. S. Sader, T. R. Fritsche, and R. N. Jones. 2005. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. *Diagn. Microbiol. Infect. Dis.* **53**:307–310.
 55. Sun, W., H. Chen, Y. Liu, C. Zhao, W. W. Nichols, M. Chen, J. Zhang, Y. Ma, and H. Wang. 2009. Prevalence and characterization of heterogeneous vancomycin-intermediate *Staphylococcus aureus* isolates from 14 cities in China. *Antimicrob. Agents Chemother.* **53**:3642–3649.
 56. Tallent, S. M., T. Bischoff, M. Climo, B. Ostrowsky, R. P. Wenzel, and M. B. Edmond. 2002. Vancomycin susceptibility of oxacillin-resistant *Staphylococcus aureus* isolates causing nosocomial bloodstream infections. *J. Clin. Microbiol.* **40**:2249–2250.
 57. Tenover, F. C., and R. C. Moellering, Jr. 2007. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for *Staphylococcus aureus*. *Clin. Infect. Dis.* **44**:1208–1215.
 58. Trakulsomboon, S., S. Danchaiwijitr, Y. Rongrungruang, C. Dhiraputra, W. Sasaemgrat, T. Ito, and K. Hiramatsu. 2001. First report of methicillin-resistant *Staphylococcus aureus* with reduced susceptibility to vancomycin in Thailand. *J. Clin. Microbiol.* **39**:591–595.
 59. Turnidge, J. D., D. Kotsanas, W. Munckhof, S. Roberts, C. M. Bennett, G. R. Nimmo, G. W. Coombs, R. J. Murray, B. Howden, P. D. Johnson, and K. Dowling. 2009. *Staphylococcus aureus* bacteraemia: a major cause of mortality in Australia and New Zealand. *Med. J. Aust.* **191**:368–373.
 60. Walsh, T. R., R. A. Howe, M. Wootton, P. M. Bennett, and A. P. MacGowan. 2001. Detection of glycopeptide resistance in *Staphylococcus aureus*. *J. Antimicrob. Chemother.* **47**:357–358.
 61. Wong, S. S., P. L. Ho, P. C. Woo, and K. Y. Yuen. 1999. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. *Clin. Infect. Dis.* **29**:760–767.